Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.


LG Electronics Shares Slide as Q3 Profit Misses Estimates
Judge Blocks Trump Election Conditions on Counterterrorism Grants
Indian Stocks Fall as RBI Hikes Rates to 5.50%
Intel Reaffirms Role in Elon Musk’s Terafab Chip Project
Securitize, LG CNS Partner on South Korea Tokenization
Zcash Prepares for NU7 Upgrade as Zebra Gets Key Security Fixes
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal
HSBC Plans Deep UK Wealth Job Cuts in AI Push
U.S. Issues Cuba Health Alert as Illnesses Rise
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
European Stocks Fall as Oil Rises Ahead of Fed Minutes
Rodrigo Duterte Makes First Public Appearance at ICC in 18 Months
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Dollar Retreats From 18-Month High as Euro Rebounds
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal
GSR Commits $100M to Hare Onchain Credit Vaults 



